VRTX Vertex Pharmaceuticals, Inc.

$VRTX Detailed RAINIER data for povetacicept in IgA nephropathy landed Friday in NEJM. The 52.0% proteinuria drop at week 36 was already known from the March topline, 49.8% vs placebo. Gd-IgA1 fell 77.4% from baseline vs a 9.1% rise on placebo, and hematuria resolved in 85.1% of patients who had it at baseline, vs 23.4% on placebo. 42.2% reached UPCR under 0.5 g/g vs 6.2% on placebo, with SGLT2 inhibitors already in 65.8% of patients. PDUFA is Nov 30, dosing is at home every 4 weeks.

$VRTX $-Billions! Don’t be distracted….Pove! Pain too- overdue for a Trial update! Sorry if these are not in order.

TRADE ALERT $VRTX setup is catalyst runup. Nov 30 PDUFA for povetacicept in IgAN is 39 days out, accelerated approval path, and RAINIER is the data behind it. 52 percent cut in proteinuria from baseline, 49.8 percent versus placebo in 605 patients entry zone $530 to $538, trading $536.79 today, up 2.3 percent stop on a close under $521 Targets: $560.25, then $579.81 it is up 10.6 percent in five sessions and just broke back above its 50 day, pushing toward that $560.25 high from September while most large caps are still chopping around. liquidity is as deep as it gets in biotech and the risk sits right under todays low imo. score 74. size it like a binary because it is one

$VRTX Latest company news, Oct 20, 2026: Vertex appointed Daniel Brennan, former CFO of Boston Scientific, to its board, which grows from 10 to 11 members; he joins the Audit and Finance Committee. More news in our $VRTX stock hub on Merlintrader. Not investment advice.

$VRTX Nov 30. 42 days out. povetacicept in IgAN cut proteinuria 52 percent in RAINIER and it still is not the story yet imo

$VRTX Bullish Harami Candlestick Pattern. Bullish Harami is a two-candlestick reversal pattern that signals a potential shift from selling pressure to buying interest after a downtrend. It forms when a small bullish candle appears entirely within the real body of the preceding large bearish candle, suggesting that bearish momentum may be weakening.

NEJM just published the full $VRTX RAINIER data Friday and the details beat the topline 52 percent proteinuria cut at week 36 versus 4.3 percent on placebo, hematuria resolved in 85 percent versus 23 percent, and 42 percent got UPCR under 0.5 versus 6 percent. Nov 30 PDUFA is 37 days out, every 4 week dosing, closed Friday at 523.93 after a 2 percent pullback, and imo the kidney story is just getting started

$VRTX 501 calls bought today strike $517.5 Oct 23 expiry. Someone expects a big move before earnings release early November.

$VRTX On watch for adding to position. Target is around 450, but happy to make small DCA purchases between 430-470.

$VRTX Overdue for Trial interim data…. Pain & Pove! Big question, how much of Repurchase program remains available?

$VRTX OptionsFLO flow and daily chart read. The alert snapshot shows $436K in the Oct 16 $525 puts. Volume was 17.5x standing open interest at capture. Daily chart through Sep 25: last close $526.19, below its 20 day average and above its 50 day average, with RSI at 53. The 3 month range is $465.00 to $560.25. Intraday volume does not establish whether a position was opened or held; the next settled open interest is the check.